Pfizer Inc. said a late-stage study of Lyrica Capsules as a treatment for adults with chronic post-traumatic peripheral neuropathic pain did not meet its primary goal. The Phase 3 trial's goal was mean pain reduction compared with a placebo, based on pain scores recorded by patients in daily pain diaries. There is currently no treatment for the ailment in the U.S., said Pfizer. Shares were up 0.5% in premarket trade, and are up 2.6% in the year, while the Dow Jones Industrial Average is down 0.1%.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below